SEC Form 3 FORM 3

UNITED STATES SECURITIES AND EXCHANGE

COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB Number: 0104

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Requiring (Month/Da	Statement y/Year)	3. Issuer Name and Ticker or Trading Symbol <u>Adicet Bio, Inc.</u> [ACET]						
		Issuer (Check all applicable)	.,		5. If Amendment, Date of Original Filed (Month/Day/Year)			
_		X Officer (give title below)		6	(Ch	6. Individual or Joint/Group Filing (Check Applicable Line) V Form filed by One Reporting		
,		Chief Scientific	Officer			Person	by More than One Person	
Table I - Non-Derivative Securities Beneficially Owned								
1. Title of Security (Instr. 4)		Beneficially Owned (Instr.			4. Nature of Indirect Beneficial Ownership (Instr. 5)			
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)								
Expiration Date		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		or Exercise		Form:	6. Nature of Indirect Beneficial Ownership (Instr.	
	Expiration Date	Title	Amount or Number of Shares	Derivative Security		or Indirect (I) (Instr. 5)	5)	
(1)	04/29/2031	Common Stock	50,000	15.9	3	D		
	Requiring (Month/Da 10/12/20 ble I - Nor ble I - Nor Table II - I , puts, cal 2. Date Exerc Expiration Da (Month/Day/N	Table II - Derivative , puts, calls, warran 2. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Date Expiration Date Expiration Date Expiration Date Expiration Date	Requiring Statement (Month/Day/Year) Adicet Bio, Inc. [A 10/12/2021 4. Relationship of Reporting Issuer (Check all applicable) Director X Officer (give title below) Able I - Non-Derivative Securities Benefic Chief Scientific Able I - Non-Derivative Securities Beneficially Owned (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) Table II - Derivative Securities Beneficia , puts, calls, warrants, options, converti 3. Title and Amount of Securities Chief Scientific 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities S	Requiring Statement (Month/Day/Year) Adicet Bio, Inc. [ACET] 10/12/2021 4. Relationship of Reporting Person(s) Issuer (Check all applicable) Director 10% O X Officer (give title below) Other (below) Able I - Non-Derivative Securities Beneficially Over Chief Scientific Officer 3. Owner Form: D (D) or In (I) (Instr. 4) Able I - Non-Derivative Securities Beneficially Over (I) (I) (Instr. 4) 3. Owner Form: D (D) or In (I) (Instr. 5) Table II - Derivative Securities Beneficially Over , puts, calls, warrants, options, convertible security (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) Date Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Shares	Requiring Statement (Month/Day/Year) Adicet Bio, Inc. [ACET] 10/12/2021 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10/12/2021 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10/00000000000000000000000000000000000	Requiring Statement (Month/Day/Year) Adicet Bio, Inc. [ACET] 10/12/2021 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) 5. If File Director 10% Owner (Check all applicable) 0ther (specify below) 6. Ir (Ch Mile I - Non-Derivative Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Na Able I - Derivative Securities Beneficially Owned , puts, calls, warrants, options, convertible securities Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security Date Expiration Date 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security	Requiring Statement (Month/Day/Year) Adicet Bio, Inc. [ACET] 10/12/2021 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 5. If Amendment, Filed (Month/Day/ 6. Individual or Jo (Check Applicable) Director 2. Officer (give (Directive) (Check Applicable) 0fficer (give (give (Directive)) 10% Owner (Security) 6. Individual or Jo (Check Applicable) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indire Ownership (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indire Ownership (Instr. 4) 7 Table II - Derivative Securities Beneficially Owned persons, convertible securities) 4. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) Date Expiration Date Title Amount of Shares 5. Ownership Price of Derivative Security 0. Ownership Or Indirect (I) (Instr. 5)	

Explanation of Responses:

1. 25% of the shares shall vest on the first anniversary of April 5, 2021 (the "Vesting Commencement Date") and as to the remaining 75% of such shares in thirty-six (36) equal monthly installments following the first anniversary of the Vesting Commencement Date; provided that the option holder remains continuously engaged by the Company on each such date.

Remarks:

/<u>s/ Nick Harvey, as</u>

Attorney-in-Fact ** Signature of Reporting Person

10/13/2021

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

OMB APPROVAL

3235-